With 63.44 million shares changed hands, the volume of the stock remained heavier than its average volume of 22.12 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $2.0400 whereas the lowest price it dropped to was $1.7400. The 52-week range on TLRY shows that it touched its highest point at $3.40 and its lowest point at $1.50 during that stretch. It currently has a 1-year price target of $2.54. Beta for the stock currently stands at 2.32.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of TLRY was up-trending over the past week, with a rise of 14.97%, but this was up by 3.78% over a month. Three-month performance dropped to -6.80% while six-month performance fell -34.47%. The stock lost -25.58% in the past year, while it has lost -16.52% so far this year. A look at the trailing 12-month EPS for TLRY yields -2.28 with Next year EPS estimates of -0.09. For the next quarter, that number is -0.05. This implies an EPS growth rate of 90.61% for this year and 60.87% for next year. EPS is expected to grow by 37.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -23.57%.
Float and Shares Shorts:
At present, 742.73 million TLRY shares are outstanding with a float of 732.79 million shares on hand for trading. On Feb 29, 2024, short shares totaled 117.51 million, which was 15.56% higher than short shares on Jan 31, 2024. In addition to Mr. Irwin David Simon as the firm’s President, CEO & Chairman, Mr. Carl A. Merton CA, CBV, CPA serves as its CFO & Principal Accounting Officer.
Institutional Ownership:
Through their ownership of 11.16% of TLRY’s outstanding shares, institutional investors have minority control over the company.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for TLRY since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.
Dividends & Yield:
In terms of dividends, TLRY has a current ratio of $––, which is $–– over the trailing 12-months, while a dividend of $–– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and TLRY currently yields $0.00. In the past year, TLRY’s dividend yield has been $0.00, but when looking at the stock over the past five years, its yield has been $–. Accordingly, TLRY has a current buyback yield of $0.00. This was $0.00 for the TTM, and it was $– for the past five years.
